What the Study Found (In Plain English)
Published in Clinical pharmacology and therapeutics (2024), this phase iii randomized trial evaluating human clinical outcomes investigated: Burosumab is indicated for treatment of a rare bone disease, X-linked hypophosphatemia (XLH). Key clinical takeaway: The analyses confirmed the importance of prolonged serum phosphate level correction in adult patients with XLH. These results can be useful to guide the design of further studies and to design treatment optimization strategies.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Clinical pharmacology and therapeutics, 2024-11-15; Phase III Randomized Trial; Rigor 82/100): The analyses confirmed the importance of prolonged serum phosphate level correction in adult patients with XLH. These results can be useful to guide the design of further studies and to design treatment optimization strategies.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.